UNICA IRIS Institutional Research Information System

ORIGA, RAFFAELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 112.601
NA - Nord America 8.178
AS - Asia 4.300
SA - Sud America 802
AF - Africa 125
OC - Oceania 9
Totale 126.015
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 109.234
US - Stati Uniti d'America 8.035
SG - Singapore 1.771
CN - Cina 1.307
NL - Olanda 1.115
BR - Brasile 646
SE - Svezia 569
VN - Vietnam 461
UA - Ucraina 451
DE - Germania 315
FI - Finlandia 267
GB - Regno Unito 200
FR - Francia 178
HK - Hong Kong 133
IN - India 115
CA - Canada 77
BD - Bangladesh 65
IQ - Iraq 60
TR - Turchia 50
PK - Pakistan 48
AR - Argentina 47
RU - Federazione Russa 46
KR - Corea 43
AT - Austria 41
MX - Messico 38
ES - Italia 37
ZA - Sudafrica 36
ID - Indonesia 32
EC - Ecuador 28
IR - Iran 26
CO - Colombia 25
JP - Giappone 24
BE - Belgio 23
MA - Marocco 22
MY - Malesia 18
PL - Polonia 18
UZ - Uzbekistan 18
TH - Thailandia 16
VE - Venezuela 16
AE - Emirati Arabi Uniti 15
EG - Egitto 15
LT - Lituania 13
CL - Cile 12
JO - Giordania 12
SA - Arabia Saudita 12
BG - Bulgaria 11
KE - Kenya 11
RO - Romania 11
TN - Tunisia 11
IL - Israele 10
PE - Perù 10
PH - Filippine 10
SI - Slovenia 10
DZ - Algeria 8
GR - Grecia 8
PY - Paraguay 8
CH - Svizzera 7
PT - Portogallo 7
AU - Australia 6
JM - Giamaica 6
KZ - Kazakistan 6
NP - Nepal 6
OM - Oman 6
PS - Palestinian Territory 6
TW - Taiwan 6
BO - Bolivia 5
DO - Repubblica Dominicana 5
ET - Etiopia 5
HN - Honduras 5
HU - Ungheria 5
IE - Irlanda 5
LB - Libano 5
AL - Albania 4
AZ - Azerbaigian 4
CI - Costa d'Avorio 4
CR - Costa Rica 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
UY - Uruguay 4
AO - Angola 3
CG - Congo 3
CY - Cipro 3
GT - Guatemala 3
LA - Repubblica Popolare Democratica del Laos 3
LV - Lettonia 3
NZ - Nuova Zelanda 3
RS - Serbia 3
BH - Bahrain 2
EE - Estonia 2
GE - Georgia 2
HR - Croazia 2
LK - Sri Lanka 2
LU - Lussemburgo 2
MT - Malta 2
PA - Panama 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BY - Bielorussia 1
GA - Gabon 1
GM - Gambi 1
Totale 126.002
Salva come PNG Salva come JPEG
Città #
Cagliari 104.943
Uta 2.942
Amsterdam 1.086
Singapore 933
Woodbridge 680
Ashburn 674
Fairfield 635
Chandler 526
San Jose 490
Dallas 395
Boardman 366
Houston 366
Nyköping 352
Ann Arbor 293
Beijing 276
Wilmington 269
Seattle 218
Cambridge 210
Jacksonville 186
Los Angeles 182
Dearborn 178
Helsinki 174
Council Bluffs 146
Santa Clara 140
Chicago 133
Ho Chi Minh City 133
Milan 121
Hong Kong 117
Lauterbourg 114
Rome 112
The Dalles 112
Boston 109
Shanghai 102
Buffalo 98
Nanjing 89
Hanoi 83
Hefei 82
New York 68
Dong Ket 64
San Diego 54
Salt Lake City 51
São Paulo 48
Guangzhou 45
Redondo Beach 42
Naples 39
Nuremberg 38
Seoul 38
Munich 30
Tampa 29
Frankfurt am Main 28
Toronto 28
Hebei 27
London 27
Redwood City 27
Brooklyn 26
Sassari 26
Orem 24
Shenyang 24
Elk Grove Village 23
Brussels 22
Da Nang 22
Tianjin 22
Tokyo 22
Baghdad 21
Changsha 21
Johannesburg 21
Montreal 21
Phoenix 21
Bari 20
Rio de Janeiro 20
Turin 20
Vienna 20
Nanchang 19
Salvador 19
Curitiba 18
Florence 18
Jiaxing 18
Jinan 17
Mountain View 17
Chennai 16
Denver 16
Verona 16
Lappeenranta 15
Manchester 15
Tashkent 15
Warsaw 15
Bologna 14
Columbus 14
Livorno 14
Atlanta 13
Haiphong 13
Seregno 13
Zhengzhou 13
Ankara 12
Catania 12
Dhaka 12
Genoa 12
Istanbul 12
Mexico City 12
Porto Alegre 12
Totale 119.556
Salva come PNG Salva come JPEG
Nome #
Thalassemia major between liver and heart: Where we are now 4.104
Current growth patterns in children and adolescents with thalassemia major 3.010
A decisional algorithm to start iron chelation in patients with beta thalassemia 2.926
A genetic score for the prediction of beta-thalassemia severity 2.913
Earlier initiation of transfusional and iron chelation therapies in recently born children with transfusion-dependent thalassemia 2.714
Deferasirox and children: From clinical trials to the real world 2.492
The V736A TMPRSS6 polymorphism influences liver iron concentration in non-transfusion-dependent thalassemias 2.359
Changes in HbA2 and HbF in alpha thalassemia carriers with KLF1 mutation 2.275
IFNL3 polymorphisms and HCV infection in patients with beta thalassemia 2.173
Natural history of hepatitis C in thalassemia major: a long-term prospective study 2.152
Causes of hospital admission in children and adults with transfusion-dependent thalassemia in Sardinia, 2000-2015 2.092
Thalassemia major: who is afraid of serum ferritin below 500 μg/l? 2.037
The problem of borderline hemoglobin A2 levels in the Screening for β-thalassemia carriers in Sardinia. 2.029
Longitudinal analysis of heart and liver iron in thalassemia major patients according to chelation treatment 1.992
Quality of life in Sardinian patients with transfusion-dependent Thalassemia: a cross-sectional study 1.984
Differences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and β-thalassemia intermedia 1.916
Investigating the Alpha 1Ncol mutation 1.873
Hematological phenotypes in children according to the α-globin genotypes 1.791
null 1.759
Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders 1.716
Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders 1.656
Complexity of the alpha-globin genotypes identified with thalassemia screening in Sardinia 1.532
Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major 1.529
Deferasirox: pharmacokinetics and clinical experience 1.454
Nuovi farmaci ferrochelanti e nuove strategie di ferro chelazione nella talassemia major 1.437
β-Thalassemia 1.431
Alpha-Thalassemia 1.348
A complicated disease: What can be done to manage thalassemia major more effectively? 1.334
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload 1.320
Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia 1.317
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload 1.279
Seasonal variation of pretransfusion hemoglobin levels in patients with thalassemia major 1.273
INTERIM RESULTS FROM A PHASE 2A, OPEN-LABEL, DOSE FINDING STUDY OF SOTATERCEPT (ACE-011) IN ADULT PATIENTS (PTS) WITH BETA-THALASSEMIA 1.191
Prospettive in Pediatria 1.182
Clinical and molecular analysis of haemoglobin H disease in Sardinia: Haematological, obstetric and cardiac aspects in patients with different genotypes 1.176
Thalassemias and Sickle Cell Diseases in Pregnancy: SITE Good Practice. 1.156
Polymorphism of S-transferase glutathione gene and a major thalassaemia cardiac iron 1.156
Combined therapy with deferiprone and desferrioxamine in thalassemia major 1.088
Glutathione S-transferase se gene polymorphism and heart iron overload in Thalassemia major 1.060
Lack of heart iron overload in patients with thalassemia intermedia. 1.016
Onset of cardiac iron loading in pediatric patients 1.011
null 1.009
Urinary hepcidin in thalassemic syndromes 905
Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-term follow up 887
null 886
Risk factors for haemorrhagic cystitis in beta thalassemic patients undergoing allogeneic haematopoietic stem cell transplant 886
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia 863
Impact of the direct-acting antiviral agents (DAAs) on chronic hepatitis C in Sardinian patients with transfusion-dependent Thalassemia major 839
Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): Results from a four years follow-up 833
Pregnancy in Thalassemia 811
Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox 783
Risk factors for endocrine complications in transfusion-dependent thalassemia patients on chelation therapy with deferasirox: a risk assessment study from a multicentre nation-wide cohort 766
Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study 762
α-globin gene quadruplication and heterozygous β-thalassemia: a not so rare cause of thalassemia intermedia 759
Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study 750
Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia 731
INTERIM RESULTS FROM A PHASE 2A, OPEN-LABEL, DOSE-FINDING STUDY TO DETERMINE THE SAFETY, EFFICACY, AND TOLERABILITY OF SOTATERCEPT (ACE-011) IN ADULTS WITH BETA-THALASSEMIA 727
Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment 717
Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study 711
Beta-thalassemia 709
Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis 698
DEFERASIROX-DEFEROXAMINE COMBINATION THERAPY REDUCES CARDIAC IRON WITH RAPID LIVER IRON REMOVAL AFTER 24 MONTHS IN PATIENTS WITH SEVERE TRANSFUSIONAL IRON OVERLOAD (HYPERION) 694
Genetic basis, pathophysiology and diagnosis 693
Changing patterns of thalassaemia in Italy: a WebThal perspective. 687
Incidence of cancer and related deaths in hemoglobinopathies: A follow-up of 4631 patients between 1970 and 2021 683
Retrospective evaluation of different iron chelators on cardiac T2* 683
A Phase 2a, Open-Label, Dose-Finding Study To Determine The Safety and Tolerability Of Sotatercept (ACE-011) In Adults With Beta (beta)-Thalassemia: Interim Results 678
Pathophysiology of beta thalassaemia 671
Relation between hypogonadism and malocclusion in beta-thalassemia major patients: analysis of 122 subjects 665
The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions 661
Pregnancy and β-thalassemia: An Italian multicenter experience 654
Beta-Thalassemia. 652
Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias 648
Renal safety under long-course deferasirox therapy in iron overloaded transfusion-dependent β-thalassemia and other anemias 640
Deferasirox-Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION) 619
null 618
Cholelithiasis in thalassemia major 610
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial 601
Lack of correlation between serum ferritin and liver iron concentration in beta-zero thalassemia intermedia 599
null 589
Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemia 583
Phenoconversion’ in adult patients with β-thalassemia 573
Crushed deferasirox film-coated tablets in pediatric patients with transfusional hemosiderosis: Results from a single-arm, interventional phase 4 study (MIMAS) 573
Sudden cardiac failure in a β-thalassemia major patient receiving chemotherapy for acute promyelocytic leukemia [5] 572
Neutropenia in patients with thalassemia major. 571
Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited 562
GDF15 and Erythroferrone Mark Erythropoietic Response to ACE-011 (Sotatercept) in Thalassemia 558
Reply to "Hepatocellular carcinoma in thalassemia and other hemoglobinopathies" 553
Transfusion Therapy in a Multi-Ethnic Sickle Cell Population Real-World Practice. a Preliminary Data Analysis of Multicentre Survey 552
null 539
Hemoglobin Utilization in Asplenic and Non-Splenectomized Transfusion Dependent Thalassemia Patients Supported with Pathogen Reduced Red Blood Cell Concentrates in a Phase 3 Study (SPARC) 538
EPO and hepcidin plasma concentrations in blood donors and β-thalassemia intermedia are not related to commercially tested plasma ERFE concentrations 535
Prima e dopo la splenectomia: terapia combinata in un paziente con compromissione cardiaca secondaria all'accumulo di ferro. 526
Selecting ß-Thalassemia Patients for Gene Therapy: A Decision-Making Algorithm 522
Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload 516
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study 515
Mortality in β-thalassemia patients with confirmed pulmonary arterial hypertension on right heart catheterization 499
Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies 497
Hepatitis C and Thalassemia: A Story with (Almost) a Happy Ending 494
The Management of Endocrine Complications in Patients with Haemoglobinopathies: Good Clinical Practice of the Italian Society of Thalassemia and Haemoglobinopathies (SITE) 490
Totale 112.398
Salva come PNG Salva come JPEG
Categoria #
all - tutte 175.981
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 175.981
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.076 0 0 0 0 0 0 0 0 0 0 991 1.085
2021/20228.150 715 540 416 589 916 841 360 487 508 817 1.092 869
2022/202311.368 1.034 1.395 1.223 756 1.008 953 471 1.504 723 737 1.026 538
2023/202413.514 644 557 523 952 1.107 2.317 2.438 854 655 1.002 1.156 1.309
2024/202524.749 4.381 4.815 4.101 3.125 1.580 1.876 1.983 153 416 1.342 692 285
2025/20267.166 714 343 908 696 581 833 1.081 507 676 814 13 0
Totale 126.582